Roivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.43

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $10.43, but opened at $10.93. Roivant Sciences shares last traded at $11.19, with a volume of 3,044,850 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ROIV. HC Wainwright upped their price objective on shares of Roivant Sciences from $17.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler began coverage on shares of Roivant Sciences in a report on Friday, January 5th. They set an “overweight” rating and a $20.00 price objective on the stock. The Goldman Sachs Group upped their price objective on shares of Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America boosted their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Wolfe Research started coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They set an “outperform” rating and a $17.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.90.

View Our Latest Stock Report on Roivant Sciences

Roivant Sciences Stock Up 5.4 %

The company has a current ratio of 27.79, a quick ratio of 27.79 and a debt-to-equity ratio of 0.06. The stock’s 50-day simple moving average is $10.78 and its 200-day simple moving average is $10.36. The firm has a market capitalization of $9.28 billion, a P/E ratio of 2.21 and a beta of 1.34.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. The firm had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. As a group, research analysts predict that Roivant Sciences Ltd. will post -1.36 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Eric Venker sold 96,950 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the transaction, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.60% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently modified their holdings of the business. Mirabella Financial Services LLP lifted its stake in shares of Roivant Sciences by 4.1% during the 3rd quarter. Mirabella Financial Services LLP now owns 34,583 shares of the company’s stock valued at $404,000 after buying an additional 1,362 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Roivant Sciences by 2.7% during the 3rd quarter. American Century Companies Inc. now owns 53,923 shares of the company’s stock valued at $630,000 after buying an additional 1,426 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Roivant Sciences by 42.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock valued at $60,000 after buying an additional 1,608 shares in the last quarter. Pathstone Family Office LLC lifted its stake in shares of Roivant Sciences by 6.1% during the 3rd quarter. Pathstone Family Office LLC now owns 38,488 shares of the company’s stock valued at $124,000 after buying an additional 2,227 shares in the last quarter. Finally, Vontobel Holding Ltd. lifted its stake in shares of Roivant Sciences by 16.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 15,782 shares of the company’s stock valued at $184,000 after buying an additional 2,258 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.